Hodgkin's disease, splenectomy and secondary leukemia.
Centurioni
R
R
Brianzoni
F
F
Leoni
P
P
Danieli
G
G
D000293:Adolescent; D000328:Adult; D000477:Alkylating Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D015994:Incidence; D007938:Leukemia / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects; D016609:Neoplasms, Second Primary / Q000453:epidemiology / Q000209:etiology*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D012306:Risk; D013156:Splenectomy / Q000009:adverse effects*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D000477:Alkylating Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone